Drug Profile
TLTS 1
Alternative Names: TLTS-1Latest Information Update: 28 Jun 2021
Price :
$50
*
At a glance
- Originator InnoMedica
- Class Antibacterials
- Mechanism of Action Bacterial growth inhibitors; Bacterial toxin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 28 Jun 2021 No recent reports of development identified for preclinical development in Bacterial-infections in Switzerland (Liposomal)
- 22 May 2017 Preclinical trials in Bacterial infections in Switzerland (Liposomal) (InnoMedica pipeline, May 2017)
- 01 Mar 2016 InnoMedica has patent protection for glycan targeting liposomal technology in Europe, Japan and USA